Spruce Biosciences
A late-stage biopharmaceutical company focused on developing novel therapies for rare endocrine disorders with significant unmet medical need.
Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal, once-daily therapy for patients suffering from classic congenital adrenal hyperplasia (CAH) and other endocrine disorders.
Latest Spruce Biosciences News & Features
14 March 2024
12 January 2023
3 July 2020
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze